How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

17,005 results for

Peripheral Neuropathy

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

16981. [Clinical observation on treatment of diabetic peripheral neuropathy with qi-supplementing and blood-activating therapy]. (Abstract)

[Clinical observation on treatment of diabetic peripheral neuropathy with qi-supplementing and blood-activating therapy]. To observe the clinical efficacy of Qi-supplementing and blood-activating (QSBA) in treating diabetic peripheral nephropathy (DPN).Sixty-eight type 2 diabetes mellitus patients with Qi deficiency-blood stasis Syndrome were randomly divided into two groups, the neurotrophic agents were used in both groups, while QSBA herbs were used in the treated group additionally

2003 Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine / Zhongguo Zhong xi yi jie he xue hui, Zhongguo Zhong yi yan jiu yuan zhu ban Controlled trial quality: uncertain

16982. Transdermal absorption of estradiol in normal subjects and in patients with peripheral neuropathies. (Abstract)

Transdermal absorption of estradiol in normal subjects and in patients with peripheral neuropathies. The relationship of disturbed autonomic skin innervation to altered transdermal absorption in polyneuropathy is not yet clear. In this study we measured serum estradiol in 29 normals and 10 polyneuropathy patients to assess potential differences of estradiol uptake from different skin sites.

2003 Clinical autonomic research : official journal of the Clinical Autonomic Research Society Controlled trial quality: uncertain

16983. Topical capsaicin in the management of HIV-associated peripheral neuropathy. (Abstract)

Topical capsaicin in the management of HIV-associated peripheral neuropathy. Distal symmetrical peripheral neuropathy (DSPN) is a particularly distressing pain syndrome associated with human immunodeficiency virus (HIV) disease. Capsaicin has been found to be effective in relieving pain associated with other neuropathic pain syndromes, and is mentioned as a possible topical adjuvant analgesic for the relief of DSPN. This multicenter, controlled, randomized, double-masked clinical trial studied

2000 Journal of pain and symptom management Controlled trial quality: uncertain

16984. [Study of the onset and progression of peripheral neuropathy and hypertension in NIDDM]. (Abstract)

[Study of the onset and progression of peripheral neuropathy and hypertension in NIDDM]. Diabetic neuropathy is the most common pathology affecting the peripheral nervous system. In prognostic terms, it is the most devastating complication of diabetes. About 50% of diabetics suffer from neuropathy between 25-30 years after the diagnosis of diabetes, even if over the past few decades there has been a considerable improvement in the diagnostic methods and criteria used to classify peripheral (...) neuropathies, many of which are related to the development of neurophysiology. However, we still do not know enough about the incidence, prevalence and natural history of peripheral neuropathy diagnosed using clinical and electrophysiological criteria in non-insulin dependent diabetic patients.The authors carried out a randomized study of the relationship between glucose intolerance, hyperglycemia, hyperinsulinemia, hypertension and early and manifest forms of peripheral neuropathy in 32 patients

2000 Minerva medica Controlled trial quality: uncertain

16985. [Clinical study on jinmaitong composita on diabetic peripheral neuropathy]. (Abstract)

[Clinical study on jinmaitong composita on diabetic peripheral neuropathy]. To verify the effect of Jinmaitong composita (JMTC) on red blood cell aldolase reductase activity (RBC-AR), RBC sorbitol (RBC-S) and nerve conductive velocity in diabetic peripheral neuropathy (DN).Sixty-six patients with DN were divided randomly into two groups, 33 patients in treated group treated with JMTC and 33 cases in the control group treated with Jinkui Shenqi (JKSQ), RBC-AR, RBC-S and nerve transmission speed (...) were observed before and after three months treatment.Level of RBC-AR, RBC-S apparently decreased and nerve conductive velocity increased (P < 0.05, P < 0.01) after TMTC treatment.JMTC was able to improve the nerve conduction significantly with a lowering of RBC-AR and RBC-S and has good result in treating Diabetic peripheral neurophathy.

1999 Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine / Zhongguo Zhong xi yi jie he xue hui, Zhongguo Zhong yi yan jiu yuan zhu ban Controlled trial quality: uncertain

16986. Randomized double-blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain. (Abstract)

Randomized double-blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain. Reports of gabapentin use in diabetic peripheral neuropathy pain stimulate a need for controlled trials to determine its comparative efficacy to the therapeutic standard of amitriptyline hydrochloride.To determine the efficacy of gabapentin compared with amitriptyline in treating diabetic peripheral neuropathy pain.Prospective, randomized, double-blind, double-dummy (...) and amitriptyline. Gabapentin may be an alternative for treating diabetic peripheral neuropathy pain, yet does not appear to offer considerable advantage over amitriptyline and is more expensive. Larger trials are necessary to define gabapentin's place in treating diabetic peripheral neuropathy pain.

1999 Archives of internal medicine Controlled trial quality: uncertain

16987. Clinical efficacy of fidarestat, a novel aldose reductase inhibitor, for diabetic peripheral neuropathy: a 52-week multicenter placebo-controlled double-blind parallel group study. (Abstract)

Clinical efficacy of fidarestat, a novel aldose reductase inhibitor, for diabetic peripheral neuropathy: a 52-week multicenter placebo-controlled double-blind parallel group study. The purpose of this study was to evaluate the efficacy of fidarestat, a novel aldose reductase (AR) inhibitor, in a double-blind placebo controlled study in patients with type 1 and type 2 diabetes and associated peripheral neuropathy.A total of 279 patients with diabetic neuropathy were treated with placebo (...) , paresthesia in the sole upon walking, heaviness in the foot, and hypesthesia) benefited from fidarestat treatment, and all were significantly improved in the treated versus placebo group at the study conclusion. At the dose used, fidarestat was well tolerated, with an adverse event profile that did not significantly differ from that seen in the placebo group.The effects of fidarestat-treatment on nerve conduction and the subjective symptoms of diabetic neuropathy provide evidence that this treatment

2001 Diabetes Care

16988. Endoneurial capillary abnormalities presage deterioration of glucose tolerance and accompany peripheral neuropathy in man. (Abstract)

Endoneurial capillary abnormalities presage deterioration of glucose tolerance and accompany peripheral neuropathy in man. To explore whether microangiopathy is associated with disturbed glucose tolerance and peripheral neuropathy, we assessed endoneurial capillary morphology in sural nerve biopsies from men with diabetes, impaired glucose tolerance (IGT), and normal glucose tolerance (NGT). Baseline morphology was related to glucose tolerance and neuropathy at baseline and at follow-up 6 years (...) ) or subjects with IGT progressing to diabetes (n = 3) compared with subjects with constant NGT (n = 6) or constant IGT (n = 4) (11.9 [2.4] vs. 20.8 [7.8]; P = 0.0201). The capillary basement membrane area (in micrometers squared) was increased in patients with peripheral neuropathy (n = 10) compared with those without (n = 7) (114.6 [68.8] vs. 75.3 [28.7]; P = 0.0084). In conclusion, increased capillary density was associated with current or future diabetes, decreased capillary luminal area with future

2003 Diabetes

16989. Mycobacterium tuberculosis infection complicated by Eales disease with peripheral neuropathy. Full Text available with Trip Pro

Mycobacterium tuberculosis infection complicated by Eales disease with peripheral neuropathy. Eales disease, which is reported mainly in patients from the Indian subcontinent, is characterized by ophthalmic abnormalities that are sometimes followed by neurologic sequelae, and it is associated with previous Mycobacterium tuberculosis infection. We describe the first patient, to our knowledge, to receive a diagnosis of active tuberculosis and concurrent, severe neurological Eales disease (...) , including peripheral neuropathy. The patient recovered completely after receiving steroid therapy.

2002 Clinical Infectious Diseases

16990. Grading of chemotherapy-induced peripheral neurotoxicity using the Total Neuropathy Scale. (Abstract)

Grading of chemotherapy-induced peripheral neurotoxicity using the Total Neuropathy Scale. The authors compared clinically based neurotoxicity scales with the Total Neuropathy Scale, with the aim of improving the grading of the severity of chemotherapy-induced peripheral neuropathy (CIPN). The severity of CIPN was evaluated in a series of 60 women treated with cisplatin- and paclitaxel-based chemotherapy. A reduced version of TNS (TNSr) was also compared. The authors concluded that the TNS (...) and TNSr can be used to assess the severity of CIPN effectively, and the results of this evaluation can be reliably correlated with the oncologic grading of sensory peripheral neurotoxicity.

2003 Neurology

16991. Peripheral neuropathies and anti-glycolipid antibodies. (Abstract)

Peripheral neuropathies and anti-glycolipid antibodies. This review charts the progress of anti-glycolipid antibodies in neuropathy, from their original discovery 20 years ago in immunoglobulin M paraproteinaemic neuropathy through to current discoveries mapping their relationship to subtypes of Guillain-Barré syndrome. Antibodies to >20 different glycolipids have now been associated with a wide range of clinically identifiable acute and chronic neuropathy syndromes. Particular progress has (...) as a potential site of injury, and led to the creation of rabbit models of anti-GD1b and anti-GM1 antibody-mediated sensory and motor neuropathy, respectively. With such information in place, it will now be possible to determine the precise mechanisms by which antibodies injure the different compartments of peripheral nerve and establish how a range of immunomodulating therapies, including current treatments, exert their therapeutic effects. Despite these very significant advances, considerable gaps in our

2002 Brain

16992. Enhanced activation of axonally transported stress-activated protein kinases in peripheral nerve in diabetic neuropathy is prevented by neurotrophin-3. Full Text available with Trip Pro

Enhanced activation of axonally transported stress-activated protein kinases in peripheral nerve in diabetic neuropathy is prevented by neurotrophin-3. The objective was to determine whether stress-activated protein kinases (SAPKs) mediated the transfer of diabetes-induced stress signals from the periphery to somata of sensory neurons. Thus, we characterized axonal transport of SAPKs in peripheral nerve, studied any alteration in streptozotocin (STZ)-diabetic rats and examined effects

2003 Brain

16993. Peripheral neuropathy in hepatitis C virus infection with and without cryoglobulinaemia. Full Text available with Trip Pro

Peripheral neuropathy in hepatitis C virus infection with and without cryoglobulinaemia. Hepatitis C virus (HCV) infection is often associated with cryoglobulinaemia (CG). Peripheral neuropathy (PN) is a comparatively common complication of CG associated with HCV infection and it is thought to be attributable to nerve ischaemia. Only few HCV CG patients with PN have been reported. The recent finding of HCV RNA in nerve biopsy specimens has suggested a possible direct role of HCV (...) + patients compared with CG- (18 of 40 compared with 1 of 11 patients; p=0.01). HCV CG- patients more frequently developed well defined mononeuropathy or multiple neuropathy when compared with HCV CG+ (10 of 11 compared with 22 of 40; p<0.03). HCV CG+ patients showed significantly higher proportion of rheumatoid factor positivity (p<0.001) and low C4 levels (p=0.001). Nerve biopsy was performed in 25 of 40 HCV CG+ patients and in 3 of 11 HCV CG- patients: epineurial vasculitis was present in 8 of 25 HCV

2003 Neurosurgery and Psychiatry

16994. Peripheral neuropathy in association with an ovarian dysgerminoma. (Abstract)

Peripheral neuropathy in association with an ovarian dysgerminoma. Peripheral neuropathy among women with ovarian dysgerminoma has not been so far reported in the literature.We report a case of an 18-year-old woman with an association of an abdominal relapse of an ovarian dysgerminoma and a polyradiculoneuritis. The normality of neurologic investigations and the disappearance of all sensitive and muscular alterations after tumor ablation and one cycle of chemotherapy are in favor

2003 Gynecologic Oncology

16995. Sympathetic mediated vasomotion and skin capillary permeability in diabetic patients with peripheral neuropathy. Full Text available with Trip Pro

Sympathetic mediated vasomotion and skin capillary permeability in diabetic patients with peripheral neuropathy. A loss of sympathetic function could lead to changes in capillary fluid filtration in diabetic patients. We investigated whether a decreased sympathetically mediated vasomotion in the skin in diabetic patients with peripheral neuropathy is associated with an abnormal capillary leakage.Three matched groups were studied: 18 diabetic patients with documented peripheral neuropathy (DN (...) ), 18 diabetic patients without peripheral neuropathy (D), and 18 healthy control subjects (C). Sensory and motor nerve function of the distal extremities were assessed by standard neurography, and expressed in a sensory-motor nerve function score. Sympathetic vasomotion of the skin microcirculation was assessed by determining the power of blood flow variability in the low-frequency (0.02-0.14 Hz) band by spectral analysis of laser Doppler flowmetry at the median ankle. Skin capillary leakage

2003 Diabetologia

16996. How should peripheral neuropathy be assessed in people with diabetes in primary care? A population-based comparison of four measures. (Abstract)

How should peripheral neuropathy be assessed in people with diabetes in primary care? A population-based comparison of four measures. To test the accuracy of four measures of peripheral diabetic neuropathy in a primary care population.Type 2 diabetic (n = 544) and 544 non-diabetic participants aged 45-76 years were randomly selected from general practice registers. Neuropathy was assessed using vibration threshold (VT) and scores for light touch, thermal sense and modified Michigan Neuropathy (...) measures had associations with risk factors for neuropathy, but light touch score (monofilament) had the strongest association with vibration threshold (the chosen gold standard) and thus appeared the most appropriate tool for use in primary care, because of its validity and simplicity of use.

2003 Diabetic Medicine

16997. The relationship between blood glucose excursions and painful diabetic peripheral neuropathy: a pilot study. (Abstract)

The relationship between blood glucose excursions and painful diabetic peripheral neuropathy: a pilot study. Peripheral neuropathy affects 30% of Type 1 diabetic patients. Unfortunately, 10-20% of affected patients have disabling symptoms. The aim of this study was to examine the relationship between blood glucose excursions and pain in patients with symptomatic diabetic neuropathy.Twenty Type 1 diabetic patients with peripheral neuropathy (10 painful and 10 painless) wore a continuous glucose (...) monitoring system for 3 days. Symptomatic patients kept a daily pain score diary. The mean amplitude of glycaemic excursions (MAGE) and the M-values (measure of glucose deviations from an arbitrarily selected point) were calculated.Groups were matched for (mean +/- sd) age: 52.0 +/- 11.1 years; duration of diabetes: 24.8 +/- 10.7 years; HbA1c: 9.7 +/- 2.3%; duration of neuropathy: 5.6 +/- 2.6 years; and CGMS performance. The painful group had a greater mean glucose (12.1 +/- 2.9 mmol/l vs. 9.3 +/- 1.9

2002 Diabetic Medicine

16998. The health care costs of diabetic peripheral neuropathy in the US. (Abstract)

The health care costs of diabetic peripheral neuropathy in the US. Peripheral neuropathy is common among people with diabetes and can result in foot ulceration and amputation. The aim of this study was to quantify the annual medical costs of peripheral neuropathy and its complications among people with type 1 and type 2 diabetes in the U.S.A cost-of-illness model was used to estimate the numbers of diabetic individuals in the U.S. who have diabetic peripheral neuropathy (DPN) and/or neuropathic

2003 Diabetes Care

16999. Intravenous immunoglobulins in peripheral neuropathy associated with vasculitis. Full Text available with Trip Pro

Intravenous immunoglobulins in peripheral neuropathy associated with vasculitis. Peripheral neuropathy is a prominent feature of the systemic and secondary vasculitides. Usually, it is responsive to corticosteroids, but in certain cases it may be resistant to corticosteroid or immunosuppressive treatment, or both.To present patients who exhibited various inflammatory diseases accompanied with vasculitic peripheral neuropathies for which intravenous immunoglobulin (IVIg) was used (...) for treatment.Six patients with Sjögren's syndrome, systemic lupus erythematosus (SLE), vaccination induced vasculitis, Churg-Strauss vasculitis, mixed cryoglobulinaemia associated with hepatitis C infection, or sarcoidosis were included. All developed vasculitic peripheral neuropathy, and were treated with high dose IVIg (2 g/kg body weight). The patients were followed up for 1-5 years after this treatment.In four patients (Sjögren's syndrome, Churg-Strauss vasculitis, SLE, and vaccination induced vasculitis

2003 Annals of the Rheumatic Diseases

17000. Peripheral neuropathies of infancy. (Abstract)

Peripheral neuropathies of infancy. Over a 33-year period, 260 patients (< 17 years of age; 119 males, 141 females) from New South Wales, Australia who had peripheral neuropathies confirmed by nerve biopsy, were studied. Of these, 50 infants presented with symptoms or signs of neuropathy under 1 year of age: including 24 patients with demyelinating neuropathies and 21 axonal neuropathies; a further five patients had spinal muscular atrophy with associated secondary sensory axonopathy. Nineteen (...) infants had hereditary motor sensory neuropathy, of whom 13 had myelin protein mutations confirmed by molecular genetic studies. Peripheral neuropathy is not an unusual diagnosis in infancy. Awareness of this association will aid early diagnosis and prognosis as well as facilitate interventional patient management.

2003 Developmental Medicine and Child Neurology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>